A virtuous synergy between the research community and investors to facilitate market access for new drugs and targeted therapies. This is the goal of Extend, the National Technology Transfer Pole, which, based on scientific publications and patents filed, has selected the University of Florence as a partner along with San Raffaele Hospital in Milan, the Universities of Milan, Modena and Reggio Emilia, Padua and Sapienza in Rome, the regional research district of Puglia through H-Bio and Human Technopole.
Launched by the National Innovation Fund -CDP Venture Capital- in partnership with Evotec and Angelini Ventures, Extend will be able to invest more than 30 million euros to create a platform where biotech research players, industrial and financial partners will collaborate to support the development of innovative solutions in the biopharmaceutical sector.
In particular, the initiative will focus on the most critical therapeutic areas, such as oncology, rare diseases, and central nervous system diseases, and will focus on biotechnology. The investment plan will fund proof of concept and start-ups to build an infrastructure that supports all stages of technology transfer from the lab to the market.
Throughout the project, Unifi professors and researchers working in the field of biotechnology and, in particular, the drug discovery sector willing to undertake entrepreneurial initiatives or to support them as founders/drivers, will be able to submit their applications according to modalities and timelines that will be communicated later.
On Wednesday, 23 November, at 2 p.m., a meeting to present the project will be held in the Great Hall of the former Deanery of Medicine (Careggi Polyclinic - Pavilion 6), during which it will also be possible to learn about the application procedure. Register online by filling out the relevant form to participate in the initiative. More info by writing to patents(AT)unifi.it
